echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > ASCO doubles the OS of specific TNBC patients with Trop-2 antibody conjugated drug Phase 3 results are positive

    ASCO doubles the OS of specific TNBC patients with Trop-2 antibody conjugated drug Phase 3 results are positive

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 5th, Gilead Sciences announced its "first-in-class" antibody-conjugated drug (ADC) Trodelvy (sacituzumab govitecan-hziy) at the ASCO annual meeting.


    Trodelvy also extended the patient's overall survival to 10.


    It is worth mentioning that Everest Medicines owns the development rights of this innovative antibody conjugate drug in Greater China.


    TNBC is an aggressive breast cancer, accounting for about 15% of all breast cancers.


    Trodelvy is a "first-in-class" antibody conjugate drug made by coupling a topoisomerase inhibitor with a monoclonal antibody targeting the Trop-2 receptor.


    "Because many patients have rapid disease progression after receiving chemotherapy, the efficacy of Trodelvy as a second-line therapy for metastatic patients is of great significance.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.